Simulator Sickness Clinical Trial
Official title:
A Double-blind Randomized Placebo Controlled Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness
BACKGROUND:flight simulator have become an important component in pilot training. However,
they are known to be associated with motion sickness like symptoms defined as Simulator
Sickness (SS). Prevention countermeasures against motion sickness have been studied
extensively focusing on cholinergic blockers and antihistamines. Most comparataive studies
emphasized the effectiveness of scopolamine over outher agents. Evidence, though, on
prophylaxis against SS is sparse.
OBJECTIVE: to assess the effectiveness of oral scopolamine versus oral cinnarizine or
placebo for SS prevention in helicopter pilots.
DESIGN: a prospective, placebo controlled double-blind.
SETTING: Israel Air Forse (IAF) Helicopter Aircaft vWeapon System Trainer.
PARTICIPANTS: IAF experienced helicopter pilots.
INTERVENTION: 0.6 mg oral scopolamine or 50 mg oral cinnarizine or placebo 1 hour before
beginning of a 3 sortie simulator training
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02122354 -
Triggers and Responses to Simulator Sickness in Videogame Players
|
N/A |